Showing results (411-420 of 531) with videos related to
Sort By:
Pageof 54
European Journal of Heart Failure|April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programmeNathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.Journal of the American College of Cardiology|June 2, 2010
A risk score to predict bleeding in patients with acute coronary syndromesRoxana Mehran, Stuart J Pocock, Eugenia Nikolsky, et al.JACC. Cardiovascular Interventions|August 22, 2009
Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudyRoxana Mehran, Eugenia Nikolsky, Alexandra J Lansky, et al.Journal of the American College of Cardiology|July 25, 2009
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trialAbhiram Prasad, Bernard J Gersh, Michel E Bertrand, et al.Lancet (London, England)|June 14, 2011
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trialGregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.The Lancet. Diabetes & Endocrinology|December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trialSubodh Verma, Nitish K Dhingra, Javed Butler, et al.The New England Journal of Medicine|May 24, 2008
Bivalirudin during primary PCI in acute myocardial infarctionGregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.Journal of the American College of Cardiology|March 23, 2019
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-ITDeepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.JAMA Network Open|April 21, 2026
Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical TrialFrancesca Rubino, Helen Mossop, David P Ripley, et al.Pageof 54